NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $622.13
  • Forecasted Upside: 7.30 %
  • Number of Analysts: 24
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 14 Buy Ratings
  • 1 Strong Buy Ratings
$579.81
▲ +4.08 (0.71%)
1 month | 3 months | 12 months
Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$622.13
▲ +7.30% Upside Potential
This price target is based on 24 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $622.13, with a high forecast of $800.00 and a low forecast of $429.00. The average price target represents a 7.30% upside from the last price of $579.81.
Buy
The current consensus among 24 contributing investment analysts is to buy stock in Regeneron Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/3/2019
  • 1 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/1/2019
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 10 hold ratings
  • 0 sell ratings
4/27/2020
  • 1 strong buy ratings
  • 16 buy ratings
  • 10 hold ratings
  • 0 sell ratings
7/26/2020
  • 1 strong buy ratings
  • 15 buy ratings
  • 10 hold ratings
  • 0 sell ratings
9/24/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 9 hold ratings
  • 0 sell ratings
10/24/2020

Latest Recommendations

  • 1 strong buy ratings
  • 14 buy ratings
  • 9 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2020Morgan StanleyLower Price TargetEqual Weight$611.00 ➝ $609.00Low
i
10/6/2020SVB LeerinkBoost Price TargetOutperform$629.00 ➝ $650.00High
i
Rating by Geoff Porges at SVB Leerink LLC
10/5/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$690.00High
i
10/1/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
8/20/2020BenchmarkDowngradeBuy ➝ HoldHigh
i
Rating by Aydin Huseynov at Benchmark Co.
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$716.00 ➝ $725.00Low
i
8/6/2020BarclaysBoost Price Target$615.00 ➝ $675.00Low
i
8/6/2020Morgan StanleyLower Price TargetEqual Weight$619.00 ➝ $611.00Low
i
8/6/2020OppenheimerBoost Price TargetOutperform$675.00 ➝ $725.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
8/6/2020CitigroupBoost Price TargetNeutral$585.00 ➝ $635.00Low
i
8/6/2020BMO Capital MarketsBoost Price TargetOutperform$525.00 ➝ $626.00Low
i
8/5/2020Goldman Sachs GroupBoost Price Target$700.00 ➝ $800.00Low
i
8/5/2020Piper SandlerBoost Price TargetOverweight$630.00 ➝ $675.00High
i
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$700.00 ➝ $716.00High
i
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$555.00 ➝ $619.00Low
i
7/8/2020SunTrust BanksUpgradeHold ➝ Buy$400.00 ➝ $750.00Low
i
7/8/2020Canaccord GenuityBoost Price TargetBuy$600.00 ➝ $700.00Low
i
7/1/2020OppenheimerBoost Price TargetOutperform$625.00 ➝ $675.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/24/2020Credit Suisse GroupBoost Price TargetOutperform$605.00 ➝ $700.00High
i
6/12/2020Jefferies Financial GroupBoost Price TargetBuy$657.00 ➝ $691.00High
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2020Jefferies Financial GroupReiterated RatingBuy$657.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2020CowenReiterated RatingHold$584.00Low
i
Rating by Yaron Werber at Cowen Inc
6/2/2020OppenheimerReiterated RatingBuy$625.00Low
i
6/2/2020Cantor FitzgeraldBoost Price TargetNeutral$400.00 ➝ $624.00Low
i
5/28/2020BarclaysBoost Price Target$530.00 ➝ $615.00High
i
5/27/2020CfraLower Price TargetHold$557.00 ➝ $549.00Low
i
5/27/2020SVB LeerinkBoost Price TargetOutperform$622.00 ➝ $625.00High
i
Rating by Geoff Porges at SVB Leerink LLC
5/26/2020SVB LeerinkReiterated RatingBuy$622.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
5/26/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$559.00 ➝ $734.00High
i
5/6/2020Robert W. BairdBoost Price TargetNeutral ➝ Neutral$487.00 ➝ $510.00High
i
5/6/2020Canaccord GenuityBoost Price TargetBuy$575.00 ➝ $630.00High
i
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$466.00 ➝ $525.00High
i
5/6/2020Royal Bank of CanadaLower Price Target$533.00 ➝ $524.00Medium
i
5/6/2020Piper SandlerBoost Price Target$550.00 ➝ $600.00Low
i
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$409.00 ➝ $555.00Medium
i
5/6/2020OppenheimerBoost Price TargetOutperform$525.00 ➝ $625.00High
i
5/6/2020Credit Suisse GroupBoost Price TargetOutperform$596.00 ➝ $605.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
5/6/2020Goldman Sachs GroupBoost Price TargetConviction-Buy$636.00 ➝ $700.00High
i
5/6/2020SVB LeerinkBoost Price TargetOutperform$604.00 ➝ $622.00High
i
5/1/2020Piper SandlerReiterated RatingOverweightLow
i
4/28/2020Canaccord GenuityBoost Price TargetBuy$550.00 ➝ $575.00Medium
i
4/28/2020CitigroupDowngradeBuy ➝ Neutral$540.00 ➝ $575.00High
i
4/19/2020BenchmarkInitiated CoverageHoldLow
i
Rating by Aydin Huseynov at Benchmark Co.
4/17/2020BMO Capital MarketsBoost Price TargetMarket Perform$379.00 ➝ $466.00High
i
4/17/2020BenchmarkUpgradeHold ➝ Buy$655.00High
i
4/15/2020Morgan StanleyLower Price TargetEqual Weight$410.00 ➝ $409.00Medium
i
4/15/2020JPMorgan Chase & Co.Boost Price TargetNeutral$375.00 ➝ $429.00Medium
i
4/8/2020BenchmarkInitiated CoverageHoldMedium
i
4/7/2020SVB LeerinkBoost Price TargetOutperform$600.00 ➝ $604.00Medium
i
4/6/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$370.00 ➝ $435.00Low
i
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$455.00High
i
3/12/2020ArgusBoost Price TargetBuy$430.00 ➝ $540.00High
i
Rating by Jasper Hellweg at Argus
3/11/2020OppenheimerBoost Price TargetOutperform$450.00 ➝ $525.00Medium
i
3/4/2020CfraBoost Price TargetBuy ➝ Hold$460.00 ➝ $487.00High
i
3/4/2020Piper SandlerBoost Price Target$435.00 ➝ $500.00High
i
2/28/2020CowenBoost Price TargetMarket Perform$386.00 ➝ $495.00High
i
Rating by Yaron Werber at Cowen Inc
2/28/2020CitigroupBoost Price TargetBuy$420.00 ➝ $540.00High
i
2/27/2020BarclaysInitiated CoverageOverweight$530.00High
i
2/26/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00Medium
i
2/26/2020Credit Suisse GroupBoost Price TargetTop Pick ➝ Outperform$420.00 ➝ $510.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
2/26/2020Robert W. BairdDowngradeOutperform ➝ Neutral$410.00High
i
2/26/2020Canaccord GenuityUpgradeHold ➝ Buy$409.00 ➝ $550.00High
i
Rating by John Newman at Canaccord Genuity
2/25/2020Jefferies Financial GroupUpgradeHold ➝ Buy$355.00 ➝ $492.00High
i
2/24/2020Evercore ISIUpgradeIn-Line ➝ Outperform$500.00High
i
Rating by Joshua Schimmer at Evercore ISI
2/11/2020ArgusUpgradeHold ➝ Buy$430.00Medium
i
2/7/2020Evercore ISIInitiated CoverageHold$400.00Low
i
Rating by Joshua Schimmer at Evercore ISI
2/7/2020Morgan StanleyLower Price TargetEqual Weight$411.00 ➝ $410.00Low
i
2/7/2020SunTrust BanksBoost Price TargetHold$400.00High
i
1/22/2020OppenheimerBoost Price TargetOutperform$430.00 ➝ $450.00Low
i
1/17/2020Morgan StanleyBoost Price TargetEqual Weight$387.00 ➝ $411.00Low
i
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
12/23/2019Raymond JamesInitiated CoverageMarket PerformN/A
i
Rating by Dane Leone at Raymond James
12/13/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
i
Rating by Evan Seigerman at Credit Suisse Group AG
12/9/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
i
11/12/2019SunTrust BanksInitiated CoverageHold$360.00Medium
i
11/11/2019Evercore ISIReiterated RatingBuy$395.00Low
i
11/6/2019CitigroupUpgradeNeutral ➝ Buy$340.00 ➝ $420.00Low
i
11/6/2019OppenheimerLower Price Target$480.00 ➝ $430.00Low
i
11/6/2019BMO Capital MarketsBoost Price TargetMarket Perform$344.00 ➝ $358.00Medium
i
Rating by Matthew Luchini at BMO Capital Markets
11/6/2019JPMorgan Chase & Co.Reiterated RatingHold$375.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/6/2019Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$310.00 ➝ $340.00Medium
i
10/16/2019Bank of AmericaInitiated CoverageNeutral$325.00Low
i
10/9/2019Canaccord GenuityLower Price TargetHold$353.00 ➝ $320.00Medium
i
10/8/2019CowenSet Price TargetHold$349.00Low
i
Rating by Yaron Werber at Cowen Inc
10/8/2019Piper Jaffray CompaniesSet Price TargetBuy$435.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
10/8/2019BMO Capital MarketsSet Price TargetHold$344.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$355.00 ➝ $403.00Low
i
8/7/2019Robert W. BairdUpgradeNeutral ➝ Outperform$410.00Low
i
8/7/2019Credit Suisse GroupLower Price TargetNeutral$333.00 ➝ $325.00Low
i
8/7/2019BMO Capital MarketsLower Price TargetMarket Perform$344.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
7/29/2019CowenReiterated RatingHold$353.00Medium
i
6/21/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
6/18/2019ArgusDowngradeBuy ➝ HoldHigh
i
6/14/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
6/11/2019SVB LeerinkSet Price TargetBuy$453.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
5/23/2019CitigroupLower Price TargetNeutral ➝ Neutral$396.00 ➝ $340.00Low
i
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$336.00High
i
5/13/2019Cantor FitzgeraldLower Price TargetNeutral$441.00 ➝ $405.00Medium
i
5/8/2019BMO Capital MarketsLower Price TargetPositive ➝ Market Perform$412.00 ➝ $375.00Medium
i
5/8/2019Morgan StanleyLower Price TargetEqual Weight$420.00 ➝ $389.00Medium
i
5/8/2019Canaccord GenuityReiterated RatingHold ➝ Hold$408.00 ➝ $353.00High
i
5/8/2019UBS GroupLower Price TargetBuy$480.00 ➝ $440.00Medium
i
5/7/2019Piper Jaffray CompaniesReiterated RatingOverweight$435.00Medium
i
5/7/2019CowenReiterated RatingHold$353.00Medium
i
4/17/2019Jefferies Financial GroupLower Price TargetHold$376.00 ➝ $343.00High
i
2/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$487.00Medium
i
2/22/2019GuggenheimDowngradeBuy ➝ Neutral$466.00 ➝ $425.00Low
i
Rating by Adnan Butt at Guggenheim
2/7/2019OppenheimerBoost Price TargetOutperform$440.00 ➝ $480.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/7/2019BMO Capital MarketsBoost Price TargetMarket Perform$412.00Low
i
2/6/2019Cantor FitzgeraldReiterated RatingHold$441.00High
i
1/7/2019CowenReiterated RatingHold$385.00Low
i
1/4/2019GuggenheimUpgradeNeutral ➝ Buy$461.00High
i
12/13/2018Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
i
12/7/2018SVB LeerinkSet Price TargetBuy$473.00 ➝ $483.00Low
i
12/2/2018OppenheimerSet Price TargetBuy$440.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/13/2018ArgusReiterated RatingBuyLow
i
11/7/2018JPMorgan Chase & Co.Set Price TargetHold$405.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/6/2018CowenReiterated RatingHold$385.00Medium
i
10/22/2018CowenReiterated RatingHold$385.00Medium
i
10/22/2018Cantor FitzgeraldBoost Price TargetNeutral$441.00Low
i
10/22/2018JPMorgan Chase & Co.Set Price TargetHold$405.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$409.00 ➝ $412.00High
i
10/11/2018Canaccord GenuityBoost Price TargetHold$390.00 ➝ $410.00High
i
10/2/2018JPMorgan Chase & Co.Reiterated RatingHoldMedium
i
10/1/2018SVB LeerinkBoost Price TargetOutperform$506.00 ➝ $512.00High
i
Rating by Geoff Porges at SVB Leerink LLC
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$415.00High
i
8/16/2018CowenReiterated RatingHold$385.00Low
i
8/6/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$290.00 ➝ $305.00Low
i
Rating by Geoff Meacham at Barclays PLC
8/3/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$304.00 ➝ $390.00Low
i
8/3/2018SunTrust BanksReiterated RatingHold$400.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$396.00 ➝ $409.00Low
i
8/3/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
i
8/2/2018BMO Capital MarketsSet Price TargetHold$388.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
7/24/2018Jefferies Financial GroupReiterated RatingHold$340.00Medium
i
7/19/2018Canaccord GenuityReiterated Rating$367.74$304.00Low
i
7/16/2018ArgusBoost Price TargetBuy ➝ Buy$383.00 ➝ $415.00Low
i
7/13/2018Morgan StanleyBoost Price TargetEqual Weight$370.00 ➝ $396.00Low
i
7/2/2018SunTrust BanksSet Price TargetHold$344.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
6/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$325.00High
i
6/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
i
5/23/2018BarclaysSet Price TargetSell$290.00Low
i
Rating by Geoff Meacham at Barclays PLC
5/7/2018Royal Bank of CanadaLower Price TargetSector Perform$342.00Low
i
5/5/2018Credit Suisse GroupSet Price TargetBuy$420.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/4/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$400.00 ➝ $370.00Low
i
5/4/2018Canaccord GenuityLower Price TargetHold ➝ Hold$356.00 ➝ $304.00Low
i
5/4/2018SVB LeerinkSet Price TargetBuy$502.00 ➝ $435.00Low
i
5/4/2018BMO Capital MarketsSet Price TargetMarket Perform ➝ Hold$398.00 ➝ $361.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
5/4/2018CowenReiterated RatingOutperform$400.00 ➝ $350.00Low
i
5/4/2018SunTrust BanksLower Price TargetHold$344.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
5/3/2018BarclaysSet Price TargetSell$290.00Low
i
Rating by Geoff Meacham at Barclays PLC
5/1/2018GuggenheimDowngradeBuy ➝ NeutralLow
i
Rating by Adnan Butt at Guggenheim
4/27/2018Credit Suisse GroupSet Price TargetBuy$420.00High
i
Rating by Alethia Young at Credit Suisse Group AG
4/27/2018CowenReiterated RatingHold$400.00Low
i
4/17/2018Credit Suisse GroupLower Price TargetBuy$440.00 ➝ $420.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/9/2018Raymond JamesReiterated RatingOutperform ➝ Market PerformLow
i
4/9/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
i
3/13/2018BTIG ResearchReiterated RatingHoldMedium
i
3/13/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$367.00Medium
i
Rating by Navin Jacob at Deutsche Bank Aktiengesellschaft
2/21/2018Canaccord GenuityDowngradeBuy ➝ Hold$522.00 ➝ $356.00Medium
i
2/13/2018BTIG ResearchReiterated RatingHoldHigh
i
2/9/2018SunTrust BanksSet Price TargetHold$430.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
2/9/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$401.00 ➝ $415.00High
i
2/9/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$568.00 ➝ $502.00High
i
2/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
i
2/9/2018GuggenheimSet Price TargetBuy$530.00High
i
2/8/2018Jefferies Financial GroupReiterated RatingNeutral ➝ Hold$380.00High
i
2/8/2018BTIG ResearchDowngradeBuy ➝ Neutral$480.00High
i
2/8/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$398.00 ➝ $444.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
2/7/2018Credit Suisse GroupSet Price TargetBuy$440.00High
i
Rating by Alethia Young at Credit Suisse Group AG
2/7/2018CowenReiterated RatingHold$450.00High
i
2/7/2018Canaccord GenuityReiterated RatingBuy$522.00High
i
Rating by John Newman at Canaccord Genuity
2/2/2018Jefferies Financial GroupReiterated RatingHold$421.00Medium
i
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$455.00 ➝ $457.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/9/2018CitigroupReiterated RatingNeutral ➝ Neutral$380.00 ➝ $388.00High
i
12/28/2017ArgusLower Price TargetPositive ➝ Buy$540.00 ➝ $470.00Low
i
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00Low
i
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$397.00Medium
i
12/1/2017CitigroupDowngradeBuy ➝ Neutral$480.00 ➝ $380.00High
i
11/28/2017JPMorgan Chase & Co.Reiterated RatingHoldMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/28/2017BTIG ResearchLower Price TargetBuy ➝ Buy$520.00 ➝ $480.00Low
i
11/27/2017BMO Capital MarketsSet Price TargetHold$444.00High
i
Rating by Matthew Luchini at BMO Capital Markets
11/22/2017BTIG ResearchReiterated RatingBuy$520.00Low
i
11/16/2017Evercore ISILower Price TargetOutperform$605.00 ➝ $445.00N/A
i
Rating by Josh Schimmer at Evercore ISI
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/9/2017Morgan StanleyLower Price TargetEqual Weight$490.00 ➝ $463.00N/A
i
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$473.00 ➝ $425.00N/A
i
11/9/2017BMO Capital MarketsLower Price TargetMarket Perform$491.00 ➝ $479.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
11/9/2017CitigroupReiterated RatingBuy$480.00N/A
i
11/3/2017Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
i
10/31/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$540.00N/A
i
10/20/2017BarclaysDowngradeEqual Weight ➝ Underweight$450.00 ➝ $395.00N/A
i
10/16/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/16/2017Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
10/6/2017Morgan StanleyReiterated RatingEqual Weight$450.00 ➝ $490.00N/A
i
10/6/2017Jefferies Financial GroupReiterated RatingHold$471.00 ➝ $500.00N/A
i
10/2/2017SunTrust BanksReiterated RatingHold$435.00Medium
i
9/29/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$540.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/27/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
9/21/2017UBS GroupLower Price TargetBuy$535.00 ➝ $500.00Medium
i
Rating by Carter Gould at UBS Group AG
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$475.00Medium
i
9/11/2017Canaccord GenuityReiterated RatingBuy$522.00Low
i
Rating by John Newman at Canaccord Genuity
9/11/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
9/8/2017Robert W. BairdReiterated RatingSell$408.00Low
i
9/7/2017CitigroupReiterated RatingBuy$575.00Low
i
9/6/2017Raymond JamesReiterated RatingOutperform ➝ Outperform$566.00Low
i
8/23/2017Morgan StanleyReiterated RatingEqual Weight$450.00Low
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$605.00Medium
i
8/15/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/15/2017SVB LeerinkReiterated RatingOutperform ➝ Positive$580.00 ➝ $552.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
8/14/2017Canaccord GenuitySet Price TargetBuy$522.00Low
i
Rating by John Newman at Canaccord Genuity
8/9/2017Jefferies Financial GroupReiterated RatingHold$418.00 ➝ $471.00Low
i
8/9/2017Goldman Sachs GroupReiterated RatingNeutral$469.00 ➝ $472.00Low
i
8/9/2017JPMorgan Chase & Co.Reiterated RatingHold$427.00 ➝ $455.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/9/2017SVB LeerinkReiterated RatingOutperform$573.00 ➝ $580.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
8/8/2017Robert W. BairdDowngradeNeutral ➝ Underperform$408.00Low
i
8/4/2017UBS GroupReiterated RatingBuy ➝ Buy$489.00 ➝ $535.00Low
i
Rating by Carter Gould at UBS Group AG
8/4/2017CitigroupBoost Price TargetBuy$555.00 ➝ $575.00Low
i
8/3/2017BMO Capital MarketsSet Price TargetHold$491.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
8/3/2017Canaccord GenuitySet Price TargetBuy$522.00Low
i
Rating by John Newman at Canaccord Genuity
8/3/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/1/2017Piper Jaffray CompaniesReiterated RatingOverweight$557.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/1/2017Robert W. BairdDowngradeNeutral ➝ Underperform$408.00High
i
7/31/2017BMO Capital MarketsReiterated RatingMarket Perform$484.00High
i
Rating by Matthew Luchini at BMO Capital Markets
7/28/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$484.00 ➝ $522.00Low
i
Rating by John Newman at Canaccord Genuity
7/22/2017BarclaysReiterated RatingEqual Weight$400.00 ➝ $450.00Low
i
7/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00 ➝ $484.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 ➝ $593.00Low
i
7/14/2017Credit Suisse GroupDowngradeHold$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
7/10/2017Morgan StanleyReiterated RatingEqual Weight$405.00 ➝ $450.00Medium
i
6/30/2017BTIG ResearchReiterated RatingBuy ➝ Buy$480.00 ➝ $540.00High
i
6/28/2017SVB LeerinkReiterated RatingOutperform$493.00 ➝ $573.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
6/26/2017Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$410.00 ➝ $480.00Low
i
6/22/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$573.00Medium
i
Rating by Geoff Porges at SVB Leerink LLC
6/22/2017Raymond JamesReiterated RatingOutperform$475.00 ➝ $547.00Medium
i
6/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
6/20/2017Canaccord GenuitySet Price TargetBuy$484.00Low
i
Rating by John Newman at Canaccord Genuity
6/20/2017Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$446.00 ➝ $557.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/14/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/13/2017SVB LeerinkReiterated RatingOutperform$493.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
5/25/2017Sanford C. BernsteinReiterated RatingOutperformHigh
i
5/15/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/15/2017CowenReiterated RatingHold$380.00Low
i
Rating by Phil Nadeau at Cowen Inc
5/15/2017BMO Capital MarketsBoost Price TargetHold$412.00 ➝ $421.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
5/8/2017BarclaysBoost Price TargetEqual Weight$375.00 ➝ $400.00Low
i
5/5/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/5/2017UBS GroupSet Price TargetBuy$446.00 ➝ $489.00N/A
i
Rating by Carter Gould at UBS Group AG
5/5/2017Canaccord GenuityUpgradeHold ➝ Buy$375.00 ➝ $484.00Low
i
Rating by John Newman at Canaccord Genuity
5/5/2017CowenReiterated RatingHold$380.00Low
i
Rating by Phil Nadeau at Cowen Inc
5/5/2017BMO Capital MarketsReiterated RatingHold$412.00 ➝ $421.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
5/4/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/12/2017Jefferies Financial GroupReiterated RatingHold$357.00Low
i
3/30/2017Canaccord GenuityReiterated RatingHold$375.00Low
i
Rating by John Newman at Canaccord Genuity
3/29/2017BTIG ResearchReiterated RatingBuy$460.00Medium
i
3/29/2017UBS GroupBoost Price TargetBuy ➝ Buy$435.00 ➝ $446.00N/A
i
Rating by Carter Gould at UBS Group AG
3/28/2017BMO Capital MarketsReiterated RatingHold$408.00 ➝ $412.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
3/28/2017SVB LeerinkSet Price TargetBuy$448.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
3/28/2017Robert W. BairdReiterated RatingNeutral$369.00Low
i
3/20/2017SVB LeerinkReiterated RatingOutperformHigh
i
Rating by Geoff Porges at SVB Leerink LLC
3/20/2017BTIG ResearchReiterated RatingBuy$460.00Low
i
3/17/2017Canaccord GenuityReiterated RatingHold$375.00Low
i
Rating by John Newman at Canaccord Genuity
3/17/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLow
i
3/16/2017OppenheimerInitiated CoverageHoldHigh
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/9/2017UBS GroupInitiated CoverageBuy ➝ Buy$435.00N/A
i
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$446.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
2/16/2017Goldman Sachs GroupDowngradeBuy ➝ NeutralN/A
i
2/16/2017Sanford C. BernsteinReiterated RatingOutperform$420.00 ➝ $410.00N/A
i
2/13/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$359.87 ➝ $446.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
2/11/2017SVB LeerinkSet Price TargetBuy$448.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
2/10/2017Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
2/10/2017Morgan StanleyLower Price TargetEqual Weight$370.00 ➝ $367.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
2/10/2017CitigroupReiterated RatingBuy$420.00N/A
i
2/10/2017Sanford C. BernsteinLower Price Target$410.00N/A
i
2/10/2017Credit Suisse GroupReiterated RatingBuy$485.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
2/9/2017CowenSet Price TargetHold$380.00N/A
i
Rating by Phil Nadeau at Cowen Inc
2/6/2017Goldman Sachs GroupLower Price TargetBuy$448.00 ➝ $446.00N/A
i
2/3/2017Canaccord GenuitySet Price TargetHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
1/22/2017JPMorgan Chase & Co.Set Price TargetHold$440.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/11/2017CowenReiterated RatingMarket Perform$400.00 ➝ $380.00N/A
i
Rating by Phil Nadeau at Cowen Inc
1/10/2017SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Geoff Porges at SVB Leerink LLC
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformN/A
i
1/9/2017Morgan StanleySet Price TargetHold$420.00 ➝ $370.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
1/8/2017Evercore ISISet Price TargetHold$421.00N/A
i
Rating by John Scotti at Evercore ISI
1/8/2017Robert W. BairdReiterated RatingNeutral$379.00 ➝ $369.00N/A
i
1/8/2017BTIG ResearchReiterated RatingBuy$460.00N/A
i
1/6/2017Royal Bank of CanadaReiterated RatingOutperform$626.00 ➝ $598.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
1/6/2017Royal Bank of CanadaLower Price TargetOutperform$626.00 ➝ $598.00N/A
i
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 ➝ $345.00N/A
i
Rating by Gbola Amusa at Chardan Capital
12/28/2016ArgusReiterated RatingBuy$450.00N/A
i
12/20/2016SVB LeerinkSet Price TargetBuy$492.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
12/20/2016BMO Capital MarketsInitiated CoverageMarket Perform$419.00N/A
i
12/20/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$481.00 ➝ $485.00N/A
i
12/16/2016BTIG ResearchUpgradeNeutral ➝ Buy$460.00N/A
i
12/12/2016Canaccord GenuitySet Price TargetHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
12/12/2016Robert W. BairdReiterated RatingPositive$379.00N/A
i
12/12/2016Chardan CapitalUpgradeSell ➝ Neutral$300.00 ➝ $350.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
12/5/2016Royal Bank of CanadaSet Price TargetBuy$626.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
12/1/2016SVB LeerinkSet Price TargetBuy$500.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
11/17/2016BTIG ResearchReiterated RatingNeutralN/A
i
11/17/2016Jefferies Financial GroupReiterated RatingHold$394.00N/A
i
11/7/2016Robert W. BairdReiterated RatingNeutral$448.00 ➝ $379.00N/A
i
Rating by Brian Skorney at Robert W. Baird
11/7/2016Chardan CapitalLower Price TargetSell$325.00 ➝ $300.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
11/6/2016Canaccord GenuitySet Price TargetHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
11/6/2016CowenSet Price TargetHold$430.00N/A
i
Rating by Phil Nadeau at Cowen Inc
11/6/2016JPMorgan Chase & Co.Set Price TargetHold$440.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2016JPMorgan Chase & Co.Set Price TargetHold$477.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2016CowenSet Price TargetHold$430.00N/A
i
Rating by Phil Nadeau at Cowen Inc
10/30/2016Piper Jaffray CompaniesSet Price TargetHold$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/25/2016SVB LeerinkSet Price TargetBuy$513.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
10/13/2016Piper Jaffray CompaniesSet Price TargetHold$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
10/12/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
10/4/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
10/4/2016Royal Bank of CanadaReiterated RatingOutperform$648.00N/A
i
Rating by adnan butt at Royal Bank of Canada
10/4/2016Robert W. BairdReiterated RatingNeutral$448.00N/A
i
Rating by Brian Skorney at Robert W. Baird
10/3/2016SVB LeerinkSet Price TargetBuy$530.00N/A
i
Rating by geoff porges at SVB Leerink LLC
9/30/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
9/30/2016Chardan CapitalReiterated RatingSell$325.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
9/27/2016Goldman Sachs GroupReiterated RatingBuy$521.00N/A
i
9/23/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
9/23/2016Robert W. BairdReiterated RatingNeutral$448.00N/A
i
Rating by Brian Skorney at Robert W. Baird
9/21/2016SVB LeerinkReiterated RatingBuy$530.00N/A
i
Rating by geoff porges at SVB Leerink LLC
9/20/2016Piper Jaffray CompaniesReiterated RatingHold$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/9/2016Piper Jaffray CompaniesReiterated RatingNeutral$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/17/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/10/2016Goldman Sachs GroupReiterated RatingBuyN/A
i
8/6/2016SVB LeerinkSet Price TargetBuy$530.00 ➝ $511.00N/A
i
Rating by geoff porges at SVB Leerink LLC
8/6/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by adnan butt at Royal Bank of Canada
8/5/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/A
i
Rating by Jason Wittes at Brean Capital
8/5/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
8/5/2016Robert W. BairdDowngradeOutperform ➝ Neutral$505.00 ➝ $448.00N/A
i
Rating by Brian Skorney at Robert W. Baird
8/5/2016CowenReiterated RatingHold$430.00N/A
i
Rating by Phil Nadeau at Cowen Inc
7/19/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/12/2016BTIG ResearchReiterated RatingHoldN/A
i
7/11/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
6/30/2016Sanford C. BernsteinReiterated RatingBuyN/A
i
Rating by Ronny Gal at Sanford C. Bernstein
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$400.00N/A
i
6/23/2016CitigroupReiterated RatingBuy$470.00N/A
i
Rating by Robyn Karnauskas at Citigroup Inc.
6/17/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by Reiterated, Today Hold at Canaccord Genuity
6/8/2016Chardan CapitalDowngradeSell$325.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
6/8/2016Wells Fargo & CompanyReiterated RatingHoldN/A
i
6/6/2016Piper Jaffray CompaniesReiterated RatingHoldN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/6/2016CowenReiterated RatingHoldN/A
i
Rating by Phil Nadeau at Cowen Inc
6/1/2016SVB LeerinkReiterated RatingOutperform$530.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
5/23/2016Wells Fargo & CompanyReiterated RatingHoldN/A
i
5/16/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Brian Skorney at Robert W. Baird
5/8/2016SVB LeerinkReiterated RatingBuy$523.00 ➝ $530.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
5/8/2016Piper Jaffray CompaniesReiterated RatingHoldN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
5/6/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
5/5/2016Robert W. BairdReiterated RatingOutperform$526.00 ➝ $505.00N/A
i
Rating by Brian Skorney at Robert W. Baird
4/30/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/20/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
4/19/2016Jefferies Financial GroupReiterated RatingHold$444.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/17/2016CowenReiterated RatingHoldN/A
i
Rating by Phil Nadeau at Cowen Inc
4/12/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jason Wittes at Brean Capital
4/9/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Reiterated, 3 days ago Buy at SVB Leerink LLC
4/8/2016Morgan StanleyLower Price Target$436.00 ➝ $415.00N/A
i
4/4/2016SVB LeerinkBoost Price TargetOutperform$505.00 ➝ $523.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/2/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Brian Skorney at Robert W. Baird
4/2/2016Roth CapitalReiterated RatingBuy$555.00 ➝ $520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
4/2/2016Piper Jaffray CompaniesReiterated RatingHold$443.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
4/1/2016UBS GroupReiterated RatingBuy$575.00N/A
i
4/1/2016Credit Suisse GroupReiterated RatingHold$481.00N/A
i
3/31/2016Canaccord GenuityReiterated RatingHold$525.00 ➝ $450.00N/A
i
Rating by John Newman at Canaccord Genuity
3/25/2016Jefferies Financial GroupLower Price TargetHold$590.00 ➝ $444.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
3/25/2016Chardan CapitalReiterated RatingSell$325.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
3/24/2016Canaccord GenuityReiterated RatingHold$525.00 ➝ $450.00N/A
i
Rating by John Newman at Canaccord Genuity
3/24/2016Piper Jaffray CompaniesReiterated RatingHoldN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/19/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Benji Star at SVB Leerink LLC
3/18/2016Goldman Sachs GroupReiterated RatingBuy$506.00N/A
i
3/17/2016SunTrust BanksLower Price TargetNeutral$450.00 ➝ $410.00N/A
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
3/16/2016Chardan CapitalDowngradeNeutral ➝ Sell$375.00 ➝ $325.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
3/15/2016Brean CapitalReiterated RatingBuy$489.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
3/15/2016GabelliInitiated CoverageBuy$574.00N/A
i
3/14/2016Jefferies Financial GroupReiterated RatingHold$444.00N/A
i
3/14/2016Canaccord GenuityReiterated RatingHold$525.00N/A
i
Rating by John Newman at Canaccord Genuity
3/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
3/13/2016Piper Jaffray CompaniesReiterated RatingHold$443.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/8/2016Brean CapitalInitiated CoverageBuy$489.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
3/3/2016SunTrust BanksInitiated CoverageNeutral$450.00N/A
i
3/1/2016Brean CapitalReiterated RatingBuy$489.00N/A
i
3/1/2016JPMorgan Chase & Co.Reiterated RatingNeutral$477.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/29/2016Canaccord GenuityReiterated RatingHold$525.00N/A
i
Rating by John Newman at Canaccord Genuity
2/25/2016CitigroupInitiated CoverageBuy$480.00N/A
i
2/22/2016Goldman Sachs GroupLower Price Target$586.00 ➝ $506.00N/A
i
2/16/2016Chardan CapitalUpgradeSell ➝ Neutral$400.00 ➝ $375.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
2/11/2016Bank of AmericaReiterated RatingBuy$649.00 ➝ $525.00N/A
i
2/10/2016Roth CapitalReiterated RatingBuy$555.00N/A
i
Rating by Joseph Pantginis at Roth Capital
2/10/2016SVB LeerinkLower Price TargetOutperform$534.00 ➝ $505.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
2/10/2016Jefferies Financial GroupLower Price Target$590.00 ➝ $444.00N/A
i
2/10/2016Goldman Sachs GroupLower Price TargetBuy$597.00 ➝ $586.00N/A
i
2/10/2016Royal Bank of CanadaReiterated RatingOutperform$676.00 ➝ $668.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
2/10/2016UBS GroupLower Price TargetBuy$645.00 ➝ $575.00N/A
i
Rating by Matt Roden at UBS Group AG
2/10/2016JPMorgan Chase & Co.Lower Price TargetNeutral$537.00 ➝ $477.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/10/2016Chardan CapitalReiterated RatingSell$400.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
2/10/2016Morgan StanleyLower Price TargetEqual Weight$583.00 ➝ $436.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
2/10/2016Brean CapitalLower Price TargetBuy$659.00 ➝ $489.00N/A
i
2/10/2016BarclaysLower Price TargetEqual Weight$610.00 ➝ $425.00N/A
i
2/9/2016Piper Jaffray CompaniesLower Price TargetNeutral$607.00 ➝ $443.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
2/9/2016Robert W. BairdReiterated RatingOutperform$674.00 ➝ $525.00N/A
i
2/6/2016SVB LeerinkReiterated RatingBuy$534.00 ➝ $505.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
2/4/2016SVB LeerinkInitiated CoverageOutperform$534.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
2/1/2016Chardan CapitalReiterated RatingSell$400.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
1/27/2016Canaccord GenuityDowngradeBuy ➝ Hold$700.00 ➝ $525.00N/A
i
Rating by John Newman at Canaccord Genuity
1/25/2016Chardan CapitalDowngradeNeutral ➝ Sell$525.00 ➝ $400.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
1/19/2016Credit Suisse GroupInitiated CoverageNeutral$552.00N/A
i
1/19/2016Roth CapitalUpgradeNeutral ➝ Buy$543.00 ➝ $555.00N/A
i
Rating by Joseph Pantginis at Roth Capital
1/13/2016Canaccord GenuityReiterated RatingBuy$700.00N/A
i
Rating by John Newman at Canaccord Genuity
1/12/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/12/2016CowenReiterated RatingMarket Perform$575.00N/A
i
Rating by Phil Nadeau at Cowen Inc
1/7/2016BTIG ResearchInitiated CoverageNeutralN/A
i
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
11/13/2015Roth CapitalReiterated RatingHold$543.00N/A
i
Rating by Joseph Pantginis at Roth Capital
11/6/2015JPMorgan Chase & Co.Reiterated RatingNeutral$578.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/5/2015SVB LeerinkReiterated RatingBuy$664.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
11/5/2015Royal Bank of CanadaBoost Price TargetOutperform$665.00 ➝ $676.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
11/4/2015CowenReiterated RatingHold$550.00 ➝ $575.00N/A
i
Rating by Phil Nadeau at Cowen Inc
11/2/2015Piper Jaffray CompaniesDowngradeOutperform ➝ NeutralN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/2/2015Morgan StanleyBoost Price TargetOutperform$489.00 ➝ $499.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
11/2/2015SVB LeerinkBoost Price Target$439.00 ➝ $445.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
10/28/2015Roth CapitalReiterated RatingHold$527.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/26/2015SVB LeerinkReiterated RatingBuy$664.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
(Data available from 10/24/2015 forward)
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $579.81
$575.12
$582.72

50 Day Range

MA: $575.74
$544.75
$607.98

52 Week Range

Now: $579.81
$299.22
$664.64

Volume

565,966 shs

Average Volume

1,255,616 shs

Market Capitalization

$61.69 billion

P/E Ratio

22.45

Dividend Yield

N/A

Beta

0.51